This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk

There are a lot of healthcare companies that are investing in GLP-1 weight loss drugs. Today, the leaders in that space are Eli Lilly and Novo Nordisk. But it could get much more crowded in the future. And it's little wonder why, given analysts project that the obesity drug market could be worth $200 billion by 2031. It's a mammoth growth opportunity that can jump-start a company's sales and profits. Before drugs are approved, investors can gain insights into just how promising a GLP-1 drug is from the results of clinical trials. One drug I've been keeping a close eye on, MariTide, comes from Amgen (NASDAQ: AMGN). Unlike the current products on the market which require weekly injections, Amgen's MariTide is taken monthly, and it has the potential to be a much more attractive option for patients.But its recent results were a concern. And they could end up giving investors more of a reason to invest in Eli Lilly and Novo Nordisk instead.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool